Thursday, 04 March 2021

Premas registers nearly 132 percent growth

11 September 2014 | Features | By BioSpectrum Bureau

Premas registers nearly 132 percent growth

Dr Prabuddha K Kundu, executive director

Dr Prabuddha K Kundu, executive director

noPosting revenue of Rs 66 crore, Premas lifesciences,a provider of industry leading molecular technologies, registered good growth in the last fiscal year. The firm's diverse product portfolio encompassing an array of high end genomics equipment and associated services has generated waves in the genetic diagnosis and research markets. Apart from lifesciences, Premas' venture into agro,food testing and forensic testing sectors played an instrumental role in boosting the firm's revenue.

Premas Lifesciences provides integrated research solutions that accelerate and solve complex lifescience challenges, improves patient diagnosis and increase laboratory productivity. In the last fiscal year, the firm unveiled its wide range of innovative products catering to the major disciples of lifesciences. The firm's latest offerings included Next Seq 500 from Illumina and C1 autoprep from Fluidigm apart from newer products like vectors, drug metabolism enzymes, reporter gene assays and nucleic acid purification kits.
Premas has completed its seventh year of association with Illumina India and has retained its distributorship from Illumina on all India operations. The firm was also chosen for a best distributor award for 2013. The company sold 25 NGS instruments in a calendar year. Nearly 24 percent of its business comes from the private sector.

Moving ahead, the firm plans to achieve 22 percent growth in revenue by exploiting markets in newer areas of lifesciences like cell biology and targets to create a consumables division apart from the existing instrumentation business. Premas also aims to tap the lucrative genomics market and is also eyeing on collaborating with international companies for global expansion.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls